BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 887,008 shares of the medical equipment provider's stock after purchasing an additional 40,416 shares during the period. Dimensional Fund Advisors LP owned approximately 1.91% of BioLife Solutions worth $23,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of BioLife Solutions during the fourth quarter worth $26,000. 1620 Investment Advisors Inc. raised its holdings in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares during the last quarter. Smartleaf Asset Management LLC grew its position in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after buying an additional 950 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in BioLife Solutions during the fourth quarter valued at $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in BioLife Solutions during the fourth quarter valued at $201,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, insider Sarah Aebersold sold 5,771 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $130,770.86. Following the completion of the sale, the insider now directly owns 80,094 shares of the company's stock, valued at $1,814,930.04. This trade represents a 6.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Todd Berard sold 1,577 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,425.00. Following the completion of the transaction, the chief marketing officer now owns 104,961 shares in the company, valued at $2,624,025. The trade was a 1.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,127 shares of company stock valued at $1,676,533. Corporate insiders own 2.20% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on BLFS. StockNews.com lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions has an average rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS traded up $0.99 during trading on Monday, hitting $24.28. The company had a trading volume of 38,488 shares, compared to its average volume of 417,778. The stock has a fifty day simple moving average of $23.84 and a two-hundred day simple moving average of $25.32. BioLife Solutions, Inc. has a fifty-two week low of $18.70 and a fifty-two week high of $29.55. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -22.90 and a beta of 2.01. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.